/
We are a leading provider of ophthalmic disease management solutions in North America, and were founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For over a decade, we have partnered with U.S. eyecare professionals to develop a comprehensive portfolio of high-quality products used to manage…
11.21% operating margin is respectable but not wide. ROIC at 8.19%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 36.4% YoY with margins expanding 6.8pp.
Net debt of $186M represents 4.3x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
$269M
▲ +36.4% YoY
Net Income (TTM)
-$15M
▲ +70.6% YoY
Op. Margin
7.32%
▲ +6.8pp YoY
ROIC
3.56%
▲ +5.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$14M
▲ +280.6% YoY
Op. Cash Flow (TTM)
$15M
▲ +297.6% YoY
Net Debt
$214M
Cash & Equiv.
$95M
5Y CAGR: +41.0%
Continue Research